Yahoo Web Search

Search results

    • Here's Why Eli Lilly Stock Remains a Screaming Buy

      Here's Why Eli Lilly Stock Remains a Screaming Buy

      Motley Fool via Yahoo Finance· 27 minutes ago

      However, the company has many more promising candidates in the hopper. Two of them -- donanemab and mirikuzumab -- already await regulatory approval. The...

    • The FDA and Gene Therapy for Duchenne Muscular Dystrophy

      Journal of the American Medical Association· 1 day ago

      The US Food and Drug Administration (FDA) grants accelerated approval that includes the standard of a surrogate outcome that is “reasonably likely” to predict clinical benefit ...